Merck & Co., Inc.
MRK
NYSE111.07
Merck & Co., Inc.
NYSE:MRK
RECENT
PRICE
111.07
P/E
RATIO
21.63
(PEG:1.96)
P/E RATIO
RELATIVE
TO S&P
0.90
DIV
YLD
3.66%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
- - Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 05/23:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Fiscal year
11.15
1.51
2.76
1.52
11.17
3.66
2.47
1.54
13.01
6.12
0.92
1.65
14.86
0.28
2.95
1.57
15.80
2.06
3.51
1.58
15.62
2.04
2.67
1.73
15.04
1.50
3.45
1.80
14.88
4.20
1.95
1.85
14.20
1.60
4.00
1.84
14.48
1.43
3.19
1.86
14.88
0.89
1.69
1.92
16.31
2.40
3.20
1.99
18.45
3.88
3.93
2.24
18.97
2.79
2.20
2.46
19.25
5.16
3.82
2.61
23.41
5.73
5.81
2.77
30.46
5.14
5.93
3.75
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.47
8.38
0.61
8.78
0.69
28.01
0.54
17.57
0.57
17.93
0.65
17.52
0.53
17.00
0.82
17.14
0.46
16.06
0.59
14.58
0.70
12.73
1.01
10.30
1.37
10.20
1.85
10.01
1.76
15.09
1.73
18.16
2.32
23.75
CAPEX per share
Book Value per share
2,171
2,136
2,109
3,095
3,041
3,027
2,928
2,838
2,781
2,749
2,697
2,593
2,539
2,530
2,530
2,532
1,900
Comm.Shares outs.(m)
33.6
1.9
3.0%
10.0
0.5
4.2%
4.8
0.1
5.6%
129.7
6.3
4.3%
16.6
1.0
4.6%
20.3
1.4
4.2%
30.8
1.8
3.9%
13.6
0.7
3.2%
35.3
1.8
3.3%
40.0
1.8
3.3%
69.7
3.0
3.1%
26.7
1.1
3.1%
21.1
0.9
2.7%
28.8
0.8
3.0%
15.0
0.5
3.4%
15.7
0.7
3.1%
21.6
0.9
3.7%
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (31/3/23 | Q1)
Total liabilities
$52,124 m.
Total assets
$98,958 m.
Long-term debt
$28,074 m.
Cash and equiv.
$9,707 m.
Goodwill $21,209 m.
Retained earnings $62,039 m.
Common stock - -
Market Capitalisation
$281,833 m. (as of 28/5/23)
47,267
20.9%
44,033
17.4%
42,237
15.8%
39,498
19.1%
39,807
15.1%
40,122
18.2%
42,294
21.1%
46,840
26.1%
47,994
17.7%
48,704
27.1%
59,283
30.8%
57,869
24.2%
Revenue (m)
Operating margin
6,978
6,168
6,988
4,404
6,691
11,920
6,375
4,442
5,441
3,920
4,637
2,394
4,519
6,220
3,652
9,843
3,625
7,067
3,214
13,049
- -
14,519
2,789
13,030
Depreciation (m)
Net profit (m)
27.9%
13.0%
18.5%
10.0%
30.9%
28.2%
17.4%
11.2%
15.4%
9.8%
62.9%
6.0%
28.8%
14.7%
14.7%
21.0%
19.4%
14.7%
11.0%
26.8%
11.7%
24.5%
14.5%
22.5%
Income tax rate
Net profit margin
16,509
16,254
53,020
17,817
20,539
49,765
14,407
18,699
48,647
10,561
23,929
44,676
13,410
24,274
40,088
6,152
21,353
34,336
3,669
19,806
26,701
5,263
22,736
25,907
437
25,360
25,317
6,394
30,690
38,184
11,483
28,745
45,991
10,271
28,074
46,834
Working capital (m)
Long-term debt (m)
Equity (m)
7.9%
9.0%
11.6%
6.0%
6.0%
8.8%
15.6%
18.3%
24.5%
6.1%
6.0%
9.9%
5.8%
5.6%
9.8%
3.9%
8.3%
7.0%
11.2%
11.5%
23.3%
17.1%
14.7%
38.0%
12.1%
10.5%
27.9%
16.7%
14.6%
34.2%
17.1%
15.1%
31.6%
15.8%
14.2%
27.8%
ROIC
Return on capital
Return on equity
Working Capital
2020
2021
2022
Cash assets
8,847
8,881
13,479
Receivables
7,851
9,230
9,450
Inventory
6,310
5,953
5,911
Other
4,756
6,987
7,169
Current assets
27,764
30,266
35,722
Acc. Payable
4,594
4,609
4,264
Debt due
6,431
2,412
1,946
Other
16,302
16,851
18,029
Current liab.
27,327
23,872
24,239
15.1%
97.0%
(19.8)%
116.7%
56.0%
233.6%
(15.2)%
83.5%
(30.7)%
97.7%
(115.8)%
201.4%
16.8%
171.7%
42.1%
105.1%
12.1%
134.6%
49.3%
77.1%
51.7%
47.7%
45.4%
64.3%
Plowback ratio
Div.&Repurch. to FCF
Merck & Co., Inc. (US) started trading on June 6, 1946 (cik: 0000310158), operates in the Healthcare sector (Drug Manufacturers—General industry), has 67,000 full-time employees, and is led by Mr. Robert M. Davis J.D.. Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
9.10%
3.65%
Cash flow
25.39%
18.92%
Earnings
31.49%
38.11%
Dividends
7.92%
3.30%
Book value
16.50%
0.97%
Insider trading
Type
Shares
Date
Mizell Steven
Exempt
13,000
05/03/23
Mizell Steven
Exempt
15,000
05/03/23
Mizell Steven
Exempt
12,000
05/03/23
Mizell Steven
Sale
13,000
05/03/23
Mizell Steven
Sale
15,000
05/03/23
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2021
12,080
11,402
13,154
13,521
50,157
2022
15,901
14,593
14,959
13,830
59,283
2023
14,487
- -
- -
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2021
1.26
0.61
1.81
1.51
5.18
2022
1.70
1.56
1.28
1.19
5.73
2023
Infinity
- -
- -
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2021
0.65
0.66
0.65
0.65
2.61
2022
0.69
0.70
0.69
0.69
2.77
2023
Infinity
- -
- -
- -
- -
04/26/2023
Merck Struggles to Expand Its Cancer-Drug Juggernaut
The Wall Street Journal - Read more...
04/18/2023
How to Tell Biotech’s Likely Winners From Losers
The Wall Street Journal - Read more...
04/16/2023
Merck to Buy Prometheus Biosciences
The Wall Street Journal - Read more...
03/06/2023
Alternatives to Popular Cholesterol Drug Cut Heart-Attack Risk
The Wall Street Journal - Read more...
02/09/2023
Pfizer, Novartis, Merck Executives Say They Are Hunting for Deals Again
The Wall Street Journal - Read more...
02/08/2023
Insurers Say Cyberattack That Hit Merck Was Warlike Act, Not Covered
The Wall Street Journal - Read more...
12/13/2022
Moderna’s mRNA Cancer Vaccine Shows Promise in Preliminary Study
The Wall Street Journal - Read more...
11/21/2022
Merck Strikes $1.35 Billion Deal for Bone-Marrow Disease Drug Developer
The Wall Street Journal - Read more...
10/31/2022
Drugmakers Fight Over Lucrative Pneumonia Vaccines
The Wall Street Journal - Read more...
10/27/2022
Merck Lifts Outlook After Quarterly Sales Rise 14%
The Wall Street Journal - Read more...
10/27/2022
Merck Shuffles Board Chairmen
The Wall Street Journal - Read more...
10/11/2022
Merck’s Patent Cliff Doesn’t Look So Frightening Anymore
The Wall Street Journal - Read more...
07/26/2022
Drugmakers Hope New Heart Drugs Boost Sales, Revive Market
The Wall Street Journal - Read more...
07/15/2022
Merck Deal for Seagen Seen as Unlikely by Earnings Release
The Wall Street Journal - Read more...
07/07/2022
Merck Is in Advanced Talks to Buy Cancer Biotech Seagen
The Wall Street Journal - Read more...
07/03/2022
Merck’s Covid-19 Pill Prescribed Often in Some Countries Despite Low Efficacy
The Wall Street Journal - Read more...
06/23/2022
Merck Pushes Forward With Potential Deal for Seagen
The Wall Street Journal - Read more...
06/22/2022
Merck Acquisition Would Test Emboldened Regulators
The Wall Street Journal - Read more...
06/18/2022
Merck Eyes Purchase of Biotech Seagen
The Wall Street Journal - Read more...
05/24/2022
Covid-19 Vaccine and Drug Sales, Once Booming, Plateau
The Wall Street Journal - Read more...
03/14/2022
Merck’s Covid-19 Pill Heavily Used So Far Despite Concerns
The Wall Street Journal - Read more...
02/03/2022
Merck, Eli Lilly Covid-19 Treatments Power Quarterly Sales Gains
The Wall Street Journal - Read more...
02/03/2022
Meta, Amazon, Snap, Pinterest: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
01/28/2022
Merck’s Covid-19 Pill Shows Promise Against Omicron
The Wall Street Journal - Read more...
01/07/2022
GameStop, AMC, DraftKings, Starbucks: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
12/23/2021
FDA Authorizes Merck’s Covid-19 Pill for At-Home Treatment
The Wall Street Journal - Read more...
12/01/2021
Salesforce, Snowflake, Zscaler, Box: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
11/30/2021
Omicron Variant Sends Policy Makers Scrambling as Science Lags Behind
The Wall Street Journal - Read more...
11/30/2021
Peloton, Moderna, Marriott, Pfizer: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
11/29/2021
Moderna, Coinbase, Occidental, Royal Caribbean: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
11/26/2021
Merck’s Covid-19 Pill Was 30% Effective in Final Analysis
The Wall Street Journal - Read more...
11/08/2021
Tesla, Coinbase, Merck: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
11/04/2021
Tesla, Moderna, Zillow, Qualcomm, Qorvo: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
11/04/2021
Merck Covid-19 Pill Cleared for Use in U.K., Its First Authorization
The Wall Street Journal - Read more...
10/28/2021
Shiba Inu Coin, Tesla, Ford, Nokia: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
10/27/2021
Promising Covid-19 Pill Licensed to Nonprofit to Increase Global Supply
The Wall Street Journal - Read more...
10/12/2021
Airbnb, Merck, High Tide, Square: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
10/11/2021
Merck Asks FDA to Authorize Promising Covid-19 Pill
The Wall Street Journal - Read more...
10/11/2021
Marathon Digital, Occidental, Southwest: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
10/04/2021
Tesla, Merck, Moderna: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
10/01/2021
Merck Pill Intended to Treat Covid-19 Succeeds in Key Study
The Wall Street Journal - Read more...
10/01/2021
AMC, Bitcoin, Lordstown, Merck: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
09/30/2021
Merck to Buy Acceleron Pharma for $11.5 Billion
The Wall Street Journal - Read more...
09/30/2021
Virgin Galactic, Camber Energy, Bed Bath & Beyond, Jefferies: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
09/28/2021
Facebook, Ford, Acceleron Pharma: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
09/27/2021
Merck Nears Deal to Acquire Acceleron Pharma
The Wall Street Journal - Read more...
07/25/2021
Race for Covid-19 Pill Heats Up
The Wall Street Journal - Read more...